The FDA said this product may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product.
Washington:
On Sunday, the US authorities announced the emergency approval of blood plasma from recovered coronavirus patients as a treatment for the disease that has killed more than 176,000 people in the United States.
The Food and Drug Administration's mandate comes as President Donald Trump faces intense pressure to curb the contagion that has crippled the world's largest economy and overshadowed its promising prospects for re-election in November.
Plasma is believed to contain powerful antibodies that can help fight disease faster and help protect people from being seriously hurt by it.
The FDA said in a statement, "This product can also be of high quality in the treatment of Kovid-19 ... and resolve the recognized and attainable danger of the product."
While the treatment has already been used on patients in the United States and other countries, experts are still debating how effective it is and some have warned that it may have side effects.
A pulmonologist at Lenox Hill Hospital in New York City said, "Convulsant plasma can also work - although it still does not wish to be valid in medical tests.
He said the plasma will likely work better after a person is exposed to the virus, when the body tries to neutralize the infection.
US media reported earlier Sunday that Trump would announce the emergency mandate at a news conference, but the White House declined to comment on the president's plans.
Trump spokeswoman Kylie McNani said the president would announce a "major treatment breakthrough."
0 Comments